Expedited Partner Therapy (EPT) for Sexually Transmitted Infections: A Resource for California Health Care Providers

Expedited Partner Therapy (EPT) is the clinical practice of treating sex partners of patients diagnosed with treatable sexually transmitted infections (STIs) – including chlamydia, gonorrhea, and trichomoniasis – without the health care provider first examining the partner(s).

This document explains what EPT is and why clinicians in California should prescribe it. In-depth references are also provided.

View PDF

July 2022 Seminar on Injectable PrEP Financing and Logistics

July 7, 2022

Slides

This guide was developed by our partners at the National Coalition for Sexual Health.

Sexual Health and Your Patients: A Provider’s Guide can help healthcare providers better integrate sexual health conversations and recommended preventive services into routine visits with adolescents and adults. By using this guide, providers can:

Become more knowledgeable about sexual health
Streamline their sexual history taking
Increase their delivery of recommended preventive sexual health services by using “at a glance” tables
Improve their care for LGBTQ+ patients
Be better prepared to discuss sexual health topics and answer patient questions

A Provider’s Guide

California STI Treatment Recommendations in Pregnancy

These treatment regimens reflect the U.S. Centers for Disease Control and Prevention (CDC) STI Treatment Guidelines that are specific to pregnant people.

View an ADA-compliant version of this table.

View PDF

California STI/HIV Screening Recommendations in Pregnancy

Reflecting California HIV/STI screening recommendations for pregnant patients at various pregnancy stages.

View an ADA-compliant version of this document.

View PDF

April 2022 Seminar on PrEP Financing and Logistics

April 28, 2022

Opt-Out ED Screening for HIV, HCV, and Syphilis—Dear Colleague Letter from CDPH

March 28, 2022: Emergency departments (EDs) are uniquely positioned to identify people with syphilis, HIV, and hepatitis C who otherwise might remain undiagnosed. The California Department of Public Health (CDPH) recommends that EDs consider implementing routine opt-out testing for syphilis, HIV, and hepatitis C.

Identification and immediate treatment through the ED may have the added benefit of furthering health equity for those disproportionately affected by these infections

View PDF

Home Training 2021 CDC STI Treatment Guidelines Update: What’s New

2021 CDC STI Treatment Guidelines Update: What’s New

December 10, 2021

Presented by Drs. Sharon Adler and Kelly Johnson

Learn more about the 2021 CDC STI Treatment Guidelines. Updated every 4-5 years, CDC’s STI Treatment Guidelines provide current evidence-based diagnostic, management, and treatment recommendations, and serve as a source of clinical guidance for managing sexually transmitted infections (STIs). This webinar will cover 2021 changes.

Learning Objectives

Learn about and become proficient with the treatment updates
Discuss and be able to share the rationale for the updates
Understand the changes needed and apply them to clinical practice

2021 PrEP Clinical Practice Guideline – Clinical Providers’ Supplement

Updated Clinical Providers’ Supplement accompanying the 2021 PrEP Clinical Practice Guideline.

Updates for 2021 include:

Checklist updated to include Descovy, 2-1-1 Truvada for MSM, and cabotegravir
Added PrEP with intramuscular cabotegravir (CAB) injections (conditional on FDA approval) recommendation for HIV prevention in adults
Added information about Descovy and cabotegravir to Patient Information Sheets

View PDF

2021 PrEP Clinical Practice Guideline

Comprehensive information for the use of antiretroviral preexposure prophylaxis (PrEP) to prevent acquiring HIV infection.

Updates for 2021 include:

A recommendation to inform all sexually active adults and adolescents about PrEP
PrEP with intramuscular cabotegravir (CAB) injections (conditional on FDA approval) is recommended for HIV prevention in adults reporting sexual behaviors that place them at substantial ongoing risk of HIV exposure and acquisition.

Also view the updated PrEP Providers Supplement for 2021.

View PDF

Comprehensive information for the use of antiretroviral preexposure prophylaxis (PrEP) to prevent acquiring HIV infection.

Updates for 2021 include:

A recommendation to inform all sexually active adults and adolescents about PrEP
PrEP with intramuscular cabotegravir (CAB) injections (conditional on FDA approval) is recommended for HIV prevention in adults reporting sexual behaviors that place them at substantial ongoing risk of HIV exposure and acquisition.

Also view the updated PrEP Providers Supplement for 2021.